Metagenomi, Inc. Common Stock
MGX · Price history
Price at last available close
$0.80
−$0.34 (-29.82%) 1M
2026-10-27
Tap or drag sideways to inspect a price. Use two fingers to compare automatically. Release to scroll. Use Shift + arrow keys to compare with a keyboard.
Company & revenue
About Metagenomi, Inc. Common Stock
Primary reporting period: 2025-12-31 · Research updated Oct 13, 2026. A research update is not a new financial filing.
Who they are
Metagenomi, Inc. operates as a biotechnology company focused on gene editing, committed to developing therapeutic solutions for patients. The company utilizes a distinctive genome editing toolkit, sourced from metagenomics, for its development efforts within the United States. This advanced toolkit comprises programmable nucleases, base editors, and sophisticated RNA and DNA-mediated integration systems, notably prime editing and CRISPR-associated transposases.
How they make money
Metagenomi Therapeutics is a biotechnology company that generates revenue primarily through research collaboration agreements. The company leverages its proprietary in vivo genome editing technologies to develop genetic medicines, entering into strategic partnerships where it receives payments for research and development activities.
Products & services
The company is an in vivo genome editing developer focused on therapeutic programs including MGX-001 for hemophilia A and research into secreted protein deficiencies such as AT-III.
Brands & revenue mix
No separate brand or brand-level revenue disclosure was confirmed in the reviewed sources. This does not mean the company has no brands.
Product / operating segments
No reconciled product or operating-segment revenue breakdown is available for the current research period. Company-wide revenue remains separate from segment disclosure.
Geographic revenue
No reconciled geographic revenue breakdown was confirmed for the current research period.
Customer types
- Pharmaceutical and biotechnology companiesSource
Customer concentration
The company's revenue is derived from a limited number of collaboration partners, which creates significant customer concentration risk.
Suppliers, materials & equipment
- Contract Research Organizations — The company utilizes unnamed third-party contract research organizations to conduct preclinical studies and clinical trial activities.Source
Competitors
- Intellia Therapeutics, Inc. — A biotechnology company developing gene editing therapies that competes in the broader genome editing and ATTR amyloidosis treatment space.Source
Strengths
- Proprietary in vivo genome editing technology platformSource
Financial risk observations and what to check
These are saved observations about business performance, not predictions. Review the company filings alongside the interpretation below. Latest stored financial period end: 2026-06-30.
Quarterly revenue fell 103.0% versus the same quarter last year.
Check comparable business scope and currency, then separate volume, pricing and divestitures. One weaker quarter does not establish that the same decline will continue.
Wall Street Score
Overall investment score · Quality, value, risk and opportunity
20
Poor
View category scores →
Company Quality
How good is the actual business—regardless of today’s stock price?
23
Poor
Financial Strength
44
Business Quality / Moat
25
Management
0
Growth Quality
0
Risk / Durability
30
Uses financial strength, moat, management, growth quality and durability. It excludes share price, P/E, market cap, intrinsic value and margin of safety.
Opportunity
Opportunity Score · How does the current price compare with estimated value?
36
Avoid
Based on current valuation, company quality, recent trends, and available market signals.
View score details →
Model Outlook
12-month model · What does the model think happens next?
43/100
Building Historical Record
Model Score 43/100 — estimates relative performance potential, distinct from the overall Wall Street Score and the separate Company Quality score.
Probability unavailable — the model has not produced a calibrated probability yet.
Click for full breakdown →
WSS View
The quick read
The overall Wall Street Score is low across its combined quality, valuation and risk inputs. This can reflect an expensive share price, business weaknesses, or both; check Company Quality and the category breakdown before drawing a conclusion.
At today’s price, the WSS valuation framework currently reads as less attractive based on the available valuation and market data.
The model outlook is currently cautious.
No strong positive signal is being highlighted from the currently available summary data.
- •Valuation is a weaker part of the current profile
- •Revenue fundamentals are weak
Company-specific research
Questions worth answering for MGX
These questions are generated from this company's current financial and score data so the page adds context instead of treating the headline score as a stand-alone conclusion.
- •What is driving MGX's revenue decline, and does the latest company filing suggest the weakness is temporary or structural?
- •How long can MGX fund negative free cash flow using its current cash position before it may need more debt or new shares?
- •Does MGX's balance between cash and debt leave enough flexibility if business conditions weaken?
- •What specifically needs to improve for MGX to reach sustainable profitability?
- •What future growth or profitability would be needed to justify MGX's current valuation?
Essential Investment Snapshot
Wall Street Score
20
Opportunity Score
36
Market Cap
$30.2M
P/E Ratio
-0.4
EPS
$-2.49
52-Week High
$3.95
52-Week Low
$1.01
Beta
0.68
Analyst Target
$14.50
Shares Outstanding
37.3M
Total Revenue
$13.6M
Total Debt
$37.7M
Dividend
No current dividend
Liquidation Value / Share
$3.02
Momentum & Volatility Signals
Two different market-behavior signals. Momentum measures direction and trend strength. Volatility measures how large and unstable the price moves are, regardless of direction.
Strong downward momentum
High movement
A high momentum score means price has been trending upward with confirming short- and medium-term strength. A low score means downward or weakening momentum.
A high volatility score means larger, less stable price swings. It can happen while a stock is rising or falling, so high volatility is not automatically bullish or bearish.
Important: the volatility score above is based on realized price volatility. Implied volatility (IV) comes from options prices and represents the market's expected future movement. Wall Street Score will keep IV separate and will only display it when a verified options-chain feed is available.
Community Sentiment
0 active · 0 total callsNo personal call yet on MGX.
Potential upside factors
- +Growth opportunities may come from revenue expansion, margin improvement, new products, market-share gains, and stronger cash flow.
- +Proprietary in vivo genome editing technology platform.
Potential downside factors
- −Key risks may include competition, margin pressure, debt levels, valuation risk, and changes in demand within the Biotechnology industry.
- −Dependence on a limited number of collaboration partners for revenue.
- −Uncertainty of clinical trial success and regulatory approval.
- −Negative free cash flow may increase the need for outside financing and dilution.
These research factors come from saved company research and financial data, not community votes. They are starting points to verify against filings, not buy or sell recommendations.
Create a free account to make a call.
Scores
Click any score for full breakdownWas this stock page easy to understand?
One click helps us improve the research experience. This is not tied to an investment decision.
Score Changes
3 historical score records availablePrevious Score
20
Oct 1, 2026
Change
Unchanged
Current Score
20
Oct 5, 2026
Category Changes
MGX score was unchanged.
Projected Score
Projected Score
25
Projected Change
+4.2 points
Preliminary comparable-period financial changes suggest improvement of approximately 4.2 points. This is a projected estimate, not the official WallStreetScore.
Price vs. Value
Valuation unavailableCurrent Price
$0.80
Model Intrinsic Value
—
Difference
—
Margin of Safety
—
Intrinsic value is not currently available for this stock, so valuation can't be calculated.
Financial Charts
Revenue
Additional Metrics
Operating Cash Flow
Total Debt
Total Assets
Net Margin %
Large reported revenue change: -51.8%
Revenue changed sharply from 2024 to 2025. This can reflect a real business change, acquisition, divestiture, discontinued operations, restatement, or reporting-basis change. Compare the underlying filing before treating it as normal growth or decline.
TTM may combine quarters from before and after the event, so its trend can also be distorted.
Free includes 3 annual periods plus available TTM; Premium includes up to 10 annual periods. History depends on available company filings. Swipe the table horizontally to see older periods. A dash means unavailable, not zero.
| Line Item | TTM | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Revenue | $13.6M | $25.2M | $52.3M | $44.8M | ···· | ···· |
| Cost of Revenue | -$41.5M | $5.3M | $0.00 | $94.4M | ···· | ···· |
| Gross Profit | $55.0M | $19.9M | $52.3M | -$49.6M | ···· | ···· |
| Research & Development | $88.6M | $94.4M | $109.2M | $94.4M | ···· | ···· |
| SG&A Expenses | $25.5M | $26.8M | $32.0M | $28.8M | ···· | ···· |
| Operating Expenses | $155.6M | $115.9M | $141.2M | $28.8M | ···· | ···· |
| EBITDA | -$88.5M | -$82.6M | -$78.2M | -$56.0M | ···· | ···· |
| Operating Income | -$100.6M | -$96.0M | -$88.9M | -$78.5M | ···· | ···· |
| Interest Expense | $0.00 | $0.00 | $0.00 | $0.00 | ···· | ···· |
| Income Before Tax | -$93.7M | -$87.9M | -$83.6M | -$60.2M | ···· | ···· |
| Income Tax Expense | -$210K | -$58K | -$5.5M | $8.0M | ···· | ···· |
| Net Income | -$93.5M | -$87.9M | -$78.1M | -$68.3M | ···· | ···· |
| Basic EPS | $-2.48 | $-2.36 | $-2.09 | $-1.82 | ···· | ···· |
| Basic Shares | 37.66M | 37.25M | 37.42M | 37.47M | ···· | ···· |
| Diluted Shares | 37.66M | 37.25M | 37.42M | 37.47M | ···· | ···· |
Earnings Summary
Revenue
-$257000
Estimate unavailable.
Revenue Beat/Miss
Not available (no estimate stored)
EPS
-$0.73
Estimate unavailable.
EPS Beat/Miss
Not available (no estimate stored)
Debt Change
-12.3%
Cash Change
+45.4%
Margin Change
+10927.2 pp
Debt and cash show percentage changes versus the comparison period; margin shows the change in percentage points (pp). These are company-wide changes, not per-share amounts.
Financial Changes Since Prior Period
What Improved
- Margins expanded
- Cash position grew
- Debt reduced
Potential Score Impact
Positive indicators included EPS growth, cash levels, debt levels, net income margin. Pressure indicators included revenue growth. These factors may support or pressure the Revenue, Management, Financial, and Debt categories; this summary does not claim that the stored scores changed.
Stored Earnings Analysis
Revenue declined 103.0%. EPS increased 35.2%. Cash increased 45.4%. Total debt declined 12.3%. Net income margin improved by 10927.2 percentage points.
Earnings-Call Transcript
Earnings-call transcript analysis is not currently available.
These results may influence future scores when the next evaluation is completed.
Insider Activity
Guru / Smart Money
Guru Score
Smart Money
Number of Gurus
Total Guru Value
Avg Portfolio Weight
Largest Holder
Largest Holder %
New Positions
Increased Positions
Reduced Positions
Exited Positions
Net Guru Sentiment
Short Interest
Dividend History
Dividend data is not available yet. Missing data does not mean this company pays no dividend.
Conservative Projected Values
3 Years
$———.——
5 Years
$———.——
10 Years
$———.——
Conservative Projection Rate
——%
Conservative Projected Values — price projections derived from actual 10-year adjusted historical returns, conservatively adjusted and capped at 8% annually. These are distinct from the Outperformance Model Score and WallStreetScore.
Conservative Projected Values
Premium unlocks the 3-year, 5-year, and 10-year conservative projected values with full calculation breakdowns based on actual historical returns.
Start 7-Day Free TrialHistorical Outperformance Record
Premium includes stored forecasts and any available evaluated results. Completed results, win rates and calibrated probabilities are shown only when supported records exist; access does not create historical outcomes.
Start 7-Day Free TrialHistorical Trends
3 historical recordsHistorical Score Chart
3 of 3 records shownWall Street Score
Debt Score
Revenue Score
Asset Score
Capital Score
Management Score
Moat Score
Valuation Score
Buffett Score
Intrinsic Value
Value Reference
Margin of Safety %
Related Companies
BiotechnologyNews
Reviewing Metagenomi (NASDAQ:MGX) and BioMarin Pharmaceutical (NASDAQ:BMRN)
Metagenomi Therapeutics, Inc. to Present at the Wells Fargo 21st Annual Healthcare Conference
Did Metagenomi Therapeutics, Inc. Insiders Breach their Fiduciary Duties to Shareholders?
MGX Resources Limited (MTGRY) Q4 2026 Earnings Call Prepared Remarks Transcript
Rumor Mill · MGX
Corporate developments & opportunities
No reviewed developments match this filter.
Evidence credibility is not a forecast of stock performance. Rumor Mill is separate from the WSS score.
Related Stock Research
Continue researching this company with related Wall Street Score rankings and investing guides.
Score Alerts
Premium unlocks alerts when a score rises, falls, or reaches your target price.
Start 7-Day Free TrialPortfolio Score
Premium unlocks portfolio scoring, strongest and weakest holdings, and overall margin of safety.
Start 7-Day Free Trial